Brief: DURECT Corp Presents Additional Clinical Data From DUR-928 Phase 1b Trial In NASH
23/06/2021 14:40
June 23 (Reuters) - DURECT Corp DRRX.O :
* DURECT - ANNOUNCED PRESENTATION OF ADDITIONAL CLINICAL
DATA FROM
DUR-928 PHASE 1B TRIAL IN NASH & PHASE 1 TRIAL IN SUBJECTS WITH
HEPATIC IMPAIRMENT
* DURECT CORP - NEW DATA FURTHER SUPPORTS DUR-928'S
POTENTIAL IN
ACUTE AND CHRONIC AS WELL AS MODERATE AND SEVERE LIVER DISEASE
Source text for Eikon: ID:nPn2dXt8na
Further company coverage: DRRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DURECT
See all newsBrief: Bausch Health Completes Acquisition Of Durect Corporation, Expanding Late-Stage Liver Disease Portfolio
Durect Corp Reports Results For The Quarter Ended June 30: Earnings Summary
Brief: Durect Bausch Health Extend Tender Offer Date To Aug 12 - SEC Filing
Durect Corp Expected To Post A Loss Of 12 Cents A Share: Earnings Preview
Durect Corp Reports Results For The Quarter Ended March 31: Earnings Summary